Chime Biologics & Mabgeek Advance MG-K10 for AD and Asthma Therapies

Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, and Mabgeek, a clinical-stage innovative antibody drug development biotech focusing on immuno-inflammation, announced the successful completion of Process Performance Qualification (PPQ) for MG-K10, a humanized anti-IL-4Ra monoclonal antibody. This milestone propels the phase III clinical trials for treating Th2-mediated inflammatory diseases such as moderate-to-severe atopic dermatitis (AD), asthma, rhinosinusitis, prurigo nodularis, esophagitis and chronic obstructive pulmonary disease (COPD).

Chime Biologics and Mabgeek’s strategic collaboration, first unveiled in 2022, focuses on commercial manufacturing of cGMP 2000L drug substance, late-stage chemistry, manufacturing, and controls (CMC) development and biologics license application (BLA) to accelerate Best-in-Class biologics MG-K10’s commercialization.

Combining Mabgeek’s expertise in monoclonal antibody innovation with Chime Biologics’ adoption of the internationally recognized quality-by-design concept, risk management methodology, and robust CMC processes, this partnership will continue to speed up development timelines while maintaining rigorous global quality standards and regulatory compliance. MG-K10 is currently the only pipeline product in this category worldwide that has been verified in late clinical study that can be dosed once every four weeks (Q4W), meeting the two key needs of strong efficacy and excellent patient adherence, which is crucial for success in the American and European markets.

Dr. Jimmy Wei, president of Chime Biologics, noted, “We are delighted with the successful completion of MG-K10’s PPQ. This achievement marks a significant milestone in our partnership and signals its immense potential in the global market. Chime Biologics upholds international quality standards, reflecting our commitment to delivering top-tier biopharmaceutical solutions that are in line with global regulatory requirements. Through our partnership with Mabgeek, we are advancing therapeutic innovation to accelerate the commercialization of MG-K10, ensuring patients worldwide receive transformative care sooner.”

Dr. Chenghai Zhang, CEO of Mabgeek, stated, “The successful PPQ for our pioneering MG-K10 antibody is a testament to the power of collaboration between us, and we are confident in entering the American and European markets, leveraging our strong innovation capabilities and commitment to meeting unmet clinical needs in allergic inflammatory diseases and autoimmune diseases. We will continue to advance this partnership with Chime Biologics to commercial manufacturing, aiming to broaden access to groundbreaking therapies for patients worldwide.”

With phase III trials underway, this collaboration remains committed to delivering Best-in-Class treatments to the market. The PPQ milestone of MG-K10 highlights Chime Biologics’ strategic approach to fostering global innovation through robust partnerships, with a particular emphasis on meeting the high standards required for success in the American and European markets.

MG-K10, a novel and long-acting humanized IL-4Ra targeting mAb drug with half-life extended,has been confirmed to have potential in treating all Th2 related disease, including AD, asthma, rhinosinusitis, prurigo nodularis, esophagitis, COPD and so on. The Phase II clinical results of MG-K10 in both AD and asthma confirmed that it has the potential to be Best-in-Class. In the phase II moderate-to-severe AD trial, MG-K10 highly improved patients’ clinical signs and quality of life, while in the phase II moderate-to-severe asthma trial, MG-K10 significantly improved lung function and clinical symptoms. While other launched anti-IL-4Ra therapeutics need to be dosed Q2W, MG-K10 is highly effective and well tolerated dosed Q4W. MG-K10 is in phase III in AD, asthma and prurigo nodularis.

Mabgeek was founded in 2016, always adhering to the research and development concept of “innovation, efficiency and safety”, focusing on the Immuno-Inflammation field. Mabgeek has a research and development team composed of top experts in the industry.

Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners’success in biologics in the whole process from cell line development to commercial manufacturing.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!